Please assess the completion status of the following clinical trial:

Trial Title: Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent~* Age \>18 \< 75 years~* Histologically/cytologically confirmed locally advanced, unresectable pancreatic cancer~* At least one lesion measurable with CT or MRI scan~* Performance Status (ECOG) 0-1 at study entry~* Life expectancy of at least 3 months~* Adequate marrow, liver and renal function~* Effective contraception if the risk of conception exists (in the Informed Consent for the patients the descriptions of possible contraceptives is reported)~Exclusion Criteria:~* Previous chemotherapy or radiotherapy for pancreatic cancer~* Severe cardiovascular disease~* Thrombotic or embolic events~* Acute or subacute intestinal occlusion or history of inflammatory bowel disease~* Known hypersensitivity to study drug~* Known drugs or alcohol abuse~* Pregnant or breastfeeding women~* Previous or concurrent malignancy; except for basal or squamous cell skin cancer and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and with evidence of no recurrence for at least 5 years prior to randomization~* Unable to sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- nab-paclitaxel and gemcitabine (Type: EXPERIMENTAL): ARM A: nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
- Gemcitabine (Type: ACTIVE_COMPARATOR): ARM B: Gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.

Based on this trial design, predict the completion outcome and termination type (if applicable).